UK markets closed

iShares $ Corp Bond ETF USD Dist (LQDA)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
14.32+0.28 (+1.99%)
At close: 04:00PM EST
14.40 +0.08 (+0.56%)
After hours: 06:37PM EST
Full screen
Trade prices are not sourced from all markets
Previous close14.04
Bid14.30 x 800
Ask14.31 x 1000
Day's range14.05 - 14.40
52-week range5.71 - 15.15
Avg. volume1,288,616
Market cap1.086B
Beta (5Y monthly)0.16
PE ratio (TTM)N/A
EPS (TTM)-0.88
Earnings date14 Mar 2024 - 18 Mar 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est21.14
  • Zacks

    United Therapeutics (UTHR) Q4 Earnings & Sales Beat Estimates

    United Therapeutics' (UTHR) fourth-quarter 2023 earnings and sales beat estimates. Tyvaso sales continue to drive the company's top line.

  • Benzinga

    United Therapeutics' Challenges FDA Over Liquidia's Drug Approval Process, Clocks Strong Q4 Earnings

    Wednesday, United Therapeutics Corporation (NASDAQ:UTHR) initiated legal action against the FDA, claiming that the FDA wrongly allowed Liquidia Corporation (NASDAQ:LQDA) to deviate from established rules in the drug approval process. The litigation focuses on the FDA’s handling of Liquidia’s amendment to a pending new drug application (NDA) related to its proposed inhaled dry powder treprostinil product, seeking to add a second indication for pulmonary hypertension associated with interstitial l

  • Reuters

    UPDATE 3-United Therapeutics starts litigation with FDA over rival Liquidia's drug application

    United Therapeutics said on Wednesday it had filed a case with the U.S. Food and Drug Administration, alleging that due procedure was not followed in allowing rival Liquidia's application for a blood pressure drug. United Therapeutics alleged that Liquidia skirted long standing FDA rules, precedents and procedures when it filed its application for an inhaled dry powder of treprostinil for pulmonary hypertension associated with interstitial lung disease (PH-ILD).